HERSHEY, Pa. — Immunotherapies that mobilize a patient’s own immune system to fight cancer have become a treatment pillar. These therapies, including CAR T-cell therapy, have performed well in cancers like leukemias and lymphomas, but the results have been less promising in solid tumors.

A team led by researchers from the Penn State College of Medicine has re-engineered immune cells so that they can penetrate and kill solid tumors grown in the lab. They created a light-activated switch that controls protein function associated with cell structure and shape and incorporated it into natural killer cells, a type of immune cell that fights infections and tumors. When these cells are exposed to blue light, they morph and can then migrate into tumor spheroids — 3D tumors grown in the lab from either mouse or human cell lines — and kill tumor cells. This novel approach could improve cell-based immunotherapies, the researchers said.

The findings were published today (Oct 23) in the Proceedings of the National Academy of Sciences. The researchers also filed a provisional application to patent the technology described in the paper.

Women are now being diagnosed with cancer more often than men in certain age groups, according to a new report from the American Cancer Society.

Among adults aged 50–64, cancer rates are slightly higher in women, and women under 50 are almost twice as likely as men in the same age group to receive a cancer diagnosis.

The report, released Thursday, found that while deaths continue to decrease, troubling racial disparities persist, with white Americans more likely to survive cancer than other groups.

Researchers publishing in Physical Review X have discovered compounds that can double the efficiency of the sirtuin SIRT3 in processing NAD+.

Looking for a new way to boost enzymes

The researchers begin their paper by noting that most drugs administered to people are geared towards inhibition of particular enzymes in order to treat a disease. In this case, however, the goal is the opposite: to boost the function of an enzyme, thereby boosting a healthy phenotype rather than battling back a diseased one.

A new way of interpreting standard blood tests could help doctors spot cancer warning signs sooner, according to scientists.

Experts believe it could flag 10,000 patients a year who have a raised blood platelet count before their cancer diagnosis — leading to ‘earlier diagnosis and better patient outcomes’